

Remarks:

Claims 1-25 were pending in the present application and claims 6-18, 22 and 24 were withdrawn from consideration as being directed to nonelected subject matter. Claims 19 to 21 and 25 in part were withdrawn from further consideration as being drawn to a nonelected subject matter. Claims 19 to 21 and 25 were amended to remove the nonelected subject matter. Applicant expressly reverses the right to claim in further applications the nonelected subject matter that was withdrawn.

35 USC §102b


Claims 1-3 and 19-21 were rejected under 35 USC §102b as being anticipated by Webber et al. Chemical Abstracts, 131:45107, 1999. Applicants have amended the claims to overcome this rejection by removing "heterocycloalkyl" as a possible substituent.

The Examiner has stated that claims 4 and 5 are objected to as being dependent upon a rejected independent claim. Applicants contend that the claims as amended are allowable and respectfully requests that the claim as amended, be allowed.

If any fee not submitted herewith is required for the filing or consideration of this amendment, including a fee for any necessary extension of time, please charge all such required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: May 9, 2005


Karl Neidert
Attorney For Applicants
Registration No. 39,313

Agouron Pharmaceuticals, Inc.
A Pfizer Company
Legal Division, Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: 858/622-8060
Fax: 858/678-8233